

Ferriprox (deferiprone)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Ferriprox (deferiprone)

APPROVAL CRITERIA

Requests for Ferriprox (deferiprone) may be approved if the following criteria are met:

1. Individual is being treated for transfusional iron overload due to thalassemia syndromes, sickle cell disease or other anemias (excluding anemia related to myelodysplastic syndrome or Diamond Blackfan anemia).

Note:

Ferriprox (deferiprone) has a black box warning for agranulocytosis/neutropenia. Ferriprox can cause agranulocytosis that can lead to serious infections and death. Neutropenia may precede the development of agranulocytosis.

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2021. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: October 11, 2021.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2021; Updated periodically.
5. NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic Syndromes. Version 1.2022. Updated October 6, 2021. Available from: https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf. Accessed: October 11, 2021.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.